CMS estimates that a proposed change in how Medicare pays hospitals for certain discounted outpatient drugs would reduce beneficiary payments by $1.15 billion in 2027. The number is not a finalized saving or a promised check. It comes from a proposed rule that would cut payment for drugs acquired through the federal 340B program, lowering coinsurance on those medicines while redistributing money elsewhere in the outpatient payment system to preserve budget neutrality.
The estimate begins with hospitals’ 340B acquisition costs
CMS’s 2027 outpatient proposed-rule fact sheet says a federal survey found large differences between hospital acquisition cost for 340B drugs and drugs bought outside that program. In some cases, the beneficiary’s ordinary 20% cost-sharing amount exceeded what the hospital itself paid to acquire the medicine.
The agency’s proposed-rule fact sheet would pay for many separately payable 340B-acquired drugs at average sales price minus 33.4%. CMS estimates that formula would reduce Original Medicare drug payments by $4.55 billion and beneficiary payments by $1.15 billion in the first year. Both figures are modeled consequences of the proposal, not audited results from 2027 claims.
The policy is aimed at hospital outpatient departments participating in 340B, a program that permits eligible safety-net providers to buy covered outpatient drugs at discounted prices. It is not a broad cut to every Medicare prescription. Part D pharmacy drugs, physician-office drugs paid under other systems and hospital medicines outside the proposal’s scope do not automatically receive the same payment change. Site of care and the hospital’s acquisition pathway determine whether the formula applies.
Free retirement updates: Social Security and Medicare change every year, and nobody sends you a memo. Our free Retirement Shield newsletter breaks down what changed and what to do. Get it free in your inbox.
Budget neutrality shifts savings across outpatient services
Federal law requires the outpatient prospective payment system to remain budget neutral. CMS therefore proposes increasing payments for non-drug outpatient services by an equivalent amount when it reduces 340B drug payments. A beneficiary can pay less coinsurance on an affected drug while seeing no comparable reduction, or even a different cost effect, on another outpatient service whose payment rises through the offset.
That redistribution distinguishes the proposal from a simple $5.7 billion cut. Medicare and patients would spend less on the covered drug claims, but hospitals would receive offsetting payment through other services. The financial result depends on the mix of drugs and non-drug care used by each beneficiary, and on how the final rule converts the systemwide offset into specific 2027 rates. National beneficiary savings can coexist with higher cost-sharing on a different service.
The official proposed-rule record is open to public comment through September 1, 2026. CMS can revise or abandon provisions after reviewing comments, data and legal arguments. Until a final rule appears, neither the minus-33.4% formula nor the $1.15 billion estimate should be treated as a settled 2027 benefit.
The history of 340B payment policy adds legal risk. Earlier Medicare cuts to payments for 340B drugs were challenged and produced a Supreme Court decision, followed by a remedy rule. That history shows how payment methodology can generate years of litigation and retrospective adjustments, making the survey basis of the new proposal central to its durability.
Patient savings would appear as lower coinsurance, not cash
Original Medicare beneficiaries generally owe a percentage of the allowed amount for separately payable outpatient drugs. When the allowed amount falls, their dollar coinsurance falls with it. The $1.15 billion estimate aggregates those reductions nationally. It does not mean every beneficiary saves money, and it does not specify an average check or rebate distributed to individuals. A person who never receives an affected drug would see no direct drug-cost reduction.
Medigap or other supplemental coverage can pay some beneficiary coinsurance, shifting who immediately captures a lower cost-sharing bill. Medicaid dual eligibility and Medicare Advantage plan design add further differences. The proposal’s modeling concerns Original Medicare beneficiary payments, while an individual’s out-of-pocket result depends on coverage layered on top of the federal allowed amount.
Hospitals argue that 340B margins finance uncompensated care and services for vulnerable patients; critics argue that percentage coinsurance tied to a payment far above acquisition cost burdens beneficiaries. The proposed formula forces that tension into the rate system. Lower drug cost-sharing can help patients at the point of care, while the budget-neutral offset protects aggregate hospital outpatient spending rather than producing the same saving for Medicare overall. Comments are likely to dispute both the survey and distribution method.
CMS’s outpatient payment page will ultimately carry the final rule and 2027 rate files. Until then, the $1.15 billion is best understood as the agency’s case for a proposal: a quantified possible benefit attached to a specific payment mechanism, with the final patient effect dependent on comments, final policy and the services each person actually receives. Only the final rate files can convert that estimate into operative payment amounts. The proposal is significant precisely because it identifies a large possible saving while leaving every implementable dollar subject to rulemaking. A final rule must settle both the drug formula and the offset before patients can count any result. Until then, no 2027 claim has been paid under the proposed rate.
Disclosure: This article was prepared with AI assistance and reviewed against current Centers for Medicare & Medicaid Services proposed-rule records.
More Financial Reading
